Acute immune toxicity during anti‐thymocyte globulin: That's CARPA!

[1]  A. Risitano,et al.  Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. , 2016, Seminars in immunology.

[2]  John D Lambris,et al.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. , 2014, Blood.

[3]  A. Risitano,et al.  Excellent Outcome of Concomitant Intensive Immunosuppression and Eculizumab in Aplastic Anemia/Paroxysmal Nocturnal Hemoglobinuria Syndrome , 2013 .

[4]  John D Lambris,et al.  Peptide inhibitors of C 3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria Supplemental Methods , 2013 .

[5]  A. Zanella,et al.  Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. , 2009, Blood.

[6]  P. Scheinberg,et al.  Apparent hemolysis following intravenous antithymocyte globulin treatment in a patient with marrow failure and a paroxysmal nocturnal hemoglobinuria clone , 2006, Transfusion.

[7]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.

[8]  D. Niederwieser,et al.  Anti-thymocyte globulin treatment of a patient for paroxysmal nocturnal haemoglobinuria-aplastic anaemia syndrome: complement activation and transient decrease of the PNH clone. , 1997, Immunobiology.

[9]  N. Young,et al.  Human Serum Sickness: A Prospective Analysis of 35 Patients Treated with Equine Anti‐Thymocyte Globulin for Bone Marrow Failure , 1988, Medicine.

[10]  N. Young,et al.  Serum sickness and haematopoietic recovery with antithymocyte globulin in bone marrow failure patients , 1986, British journal of haematology.

[11]  N. Young,et al.  A prospective clinical and immunologic analysis of patients with serum sickness. , 1984, The New England journal of medicine.